ECSP22038978A - INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA - Google Patents
INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANAInfo
- Publication number
- ECSP22038978A ECSP22038978A ECSENADI202238978A ECDI202238978A ECSP22038978A EC SP22038978 A ECSP22038978 A EC SP22038978A EC SENADI202238978 A ECSENADI202238978 A EC SENADI202238978A EC DI202238978 A ECDI202238978 A EC DI202238978A EC SP22038978 A ECSP22038978 A EC SP22038978A
- Authority
- EC
- Ecuador
- Prior art keywords
- alpha4ß7
- inhibition
- human integrin
- integrin
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Radio Relay Systems (AREA)
- Air Conditioning Control Device (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Moléculas pequeñas antagonistas de la integrina humana Alfa4ß7, y métodos para usarlas en el tratamiento de varias enfermedades y afecciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962916062P | 2019-10-16 | 2019-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22038978A true ECSP22038978A (es) | 2022-06-30 |
Family
ID=73198501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202238978A ECSP22038978A (es) | 2019-10-16 | 2022-05-16 | INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US20240174632A1 (es) |
| EP (3) | EP4559525A3 (es) |
| JP (7) | JP7437490B2 (es) |
| KR (2) | KR20220102669A (es) |
| CN (3) | CN119192137A (es) |
| AR (1) | AR120244A1 (es) |
| AU (2) | AU2020366435A1 (es) |
| BR (1) | BR112022007284A2 (es) |
| CA (1) | CA3154269A1 (es) |
| CL (1) | CL2022000959A1 (es) |
| CO (1) | CO2022005759A2 (es) |
| CR (1) | CR20220205A (es) |
| CU (1) | CU20220027A7 (es) |
| DK (1) | DK4045039T3 (es) |
| DO (2) | DOP2022000081A (es) |
| EC (1) | ECSP22038978A (es) |
| ES (1) | ES3035561T3 (es) |
| FI (1) | FI4045039T3 (es) |
| HR (1) | HRP20250749T1 (es) |
| HU (1) | HUE071814T2 (es) |
| IL (2) | IL319053A (es) |
| LT (1) | LT4045039T (es) |
| MA (1) | MA57399B1 (es) |
| MD (1) | MD4045039T2 (es) |
| MX (1) | MX2022004406A (es) |
| PE (1) | PE20221829A1 (es) |
| PH (1) | PH12022550886A1 (es) |
| PL (1) | PL4045039T3 (es) |
| PT (1) | PT4045039T (es) |
| RS (1) | RS66976B1 (es) |
| SI (1) | SI4045039T1 (es) |
| TW (7) | TWI775182B (es) |
| UA (1) | UA130059C2 (es) |
| UY (1) | UY38926A (es) |
| WO (3) | WO2021076890A1 (es) |
| ZA (2) | ZA202203872B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3773573A4 (en) | 2018-04-12 | 2022-04-06 | Morphic Therapeutic, Inc. | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4) (BETA7) |
| HRP20250191T1 (hr) | 2018-10-30 | 2025-04-11 | Gilead Sciences, Inc. | Derivati 3-(kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-diona kao inhibitori alfa4beta7 integrina za liječenje upalnih bolesti |
| JP7656547B2 (ja) | 2019-05-15 | 2025-04-03 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１疾患治療用のトリアリール化合物 |
| EP4013499A1 (en) | 2019-08-14 | 2022-06-22 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| PH12022550877A1 (en) | 2019-10-16 | 2023-03-27 | Chemocentryx Inc | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases |
| BR112022006018A2 (pt) | 2019-10-16 | 2022-07-12 | Chemocentryx Inc | Heteroaril-bifenil amidas para o tratamento de doenças relacionadas à pd-l1 |
| RS66976B1 (sr) * | 2019-10-16 | 2025-07-31 | Morphic Therapeutic Inc | Inhibiranje ljudskog integrina alfa4beta7 |
| US20250195485A1 (en) * | 2021-12-27 | 2025-06-19 | Xizang Haisco Pharmaceutical Co., Ltd. | Propionic acid derivative and medical use thereof |
| EP4585587A1 (en) | 2022-09-09 | 2025-07-16 | Xizang Haisco Pharmaceutical Co., Ltd. | Propionic acid derivative and use thereof in medicine |
| JP2025542171A (ja) | 2022-12-22 | 2025-12-25 | シンセラ， インコーポレイテッド | アルファ４ベータ７インテグリンアンタゴニスト及びその使用 |
| WO2024175907A1 (en) * | 2023-02-21 | 2024-08-29 | C4X Discovery Limited | Macrocyclic alpha4beta7 integrin inhibitors |
| AU2024279767A1 (en) | 2023-05-26 | 2025-12-04 | Adarx Pharmaceuticals, Inc. | Sod1-modulating compositions and methods of use thereof |
| WO2025026955A1 (en) * | 2023-07-28 | 2025-02-06 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2025176107A1 (zh) * | 2024-02-20 | 2025-08-28 | 西藏海思科制药有限公司 | 一种吡啶酮衍生物及其在医药上的应用 |
| CN118702712B (zh) * | 2024-07-04 | 2025-11-11 | 安徽普利药业有限公司 | 一种n-(3-苯10硼酸)-l-天冬氨酸中间体制备方法 |
| WO2026018017A1 (en) * | 2024-07-19 | 2026-01-22 | C4X Discovery Limited | Therapeutic compounds |
| WO2026018016A1 (en) * | 2024-07-19 | 2026-01-22 | C4X Discovery Limited | Therapeutic compounds |
| CN119504796A (zh) * | 2024-11-20 | 2025-02-25 | 南通大学附属医院 | 一种具有抗肿瘤活性的化合物及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE195117T1 (de) | 1993-03-31 | 2000-08-15 | Searle & Co | 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren |
| DE4427979A1 (de) | 1993-11-15 | 1996-02-15 | Cassella Ag | Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung |
| US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| DE19622489A1 (de) | 1996-06-05 | 1997-12-11 | Hoechst Ag | Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters |
| AU743735B2 (en) | 1996-10-11 | 2002-02-07 | Millennium Pharmaceuticals, Inc. | Selective factor Xa inhibitors |
| CA2268270A1 (en) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | Heterocyclic derivatives as factor xa inhibitors |
| DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
| AU751950B2 (en) * | 1997-11-24 | 2002-09-05 | Merck & Co., Inc. | Substituted beta-alanine derivatives as cell adhesion inhibitors |
| US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| EP1091945A1 (en) | 1998-06-29 | 2001-04-18 | Du Pont Pharmaceuticals Company | Cyclic carbamates and isoxazolidines as iib/iiia antagonists |
| AU747784B2 (en) * | 1998-07-29 | 2002-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
| GB9826174D0 (en) * | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| US6723711B2 (en) * | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| MXPA01011341A (es) * | 1999-05-07 | 2002-06-21 | Texas Biotechnology Corp | Derivados de acido propanoico que inhiben la union de las integrinas a sus receptores. |
| WO2001021584A1 (en) | 1999-09-24 | 2001-03-29 | Genentech, Inc. | Tyrosine derivatives |
| DE10041423A1 (de) | 2000-08-23 | 2002-03-07 | Merck Patent Gmbh | Biphenylderivate |
| EA200300226A1 (ru) * | 2000-08-30 | 2003-10-30 | Фармасиа Корпорейшн | ГЕМ-ЗАМЕЩЕННЫЕ АНТАГОНИСТЫ ИНТЕГРИНА αvβ3 |
| DE10111876A1 (de) | 2001-03-10 | 2002-09-19 | Aventis Pharma Gmbh | Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe |
| DE10154280A1 (de) | 2001-11-05 | 2003-05-15 | Wilex Ag | Antagonisten für alpha¶4¶-Integrine |
| EP1485127B1 (en) | 2002-02-25 | 2011-06-08 | Elan Pharmaceuticals, Inc. | Administration of agents for the treatment of inflammation |
| KR101364276B1 (ko) | 2004-09-03 | 2014-02-20 | 제넨테크, 인크. | 인간화 항-베타７ 길항제 및 그의 용도 |
| ES2387317T3 (es) | 2005-03-03 | 2012-09-20 | Seedlings Life Science Ventures, Llc. | Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab |
| WO2006126529A1 (ja) | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体 |
| DE602006019731D1 (de) | 2005-06-09 | 2011-03-03 | Ucb Pharma Sa | 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel |
| EP3620469A1 (en) | 2006-02-28 | 2020-03-11 | Biogen MA Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| US20100272680A1 (en) | 2009-02-09 | 2010-10-28 | Subramanian Baskaran | Piperidinyl Cyclic Amido Antiviral Agents |
| RU2595836C2 (ru) | 2011-03-31 | 2016-08-27 | Дженентек, Инк. | Способы введения антагонистов интегрина бета7 |
| MX372664B (es) | 2012-10-05 | 2020-05-06 | Genentech Inc | Un antagonista de integrina beta7 para usarse en diagnosticar y tratar la enfermedad inflamatoria intestinal. |
| CN106102767B (zh) | 2014-03-27 | 2021-08-10 | 豪夫迈·罗氏有限公司 | 用于诊断和治疗炎症性肠病的方法 |
| CN105658641B (zh) | 2014-07-25 | 2018-04-17 | 江苏恒瑞医药股份有限公司 | 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用 |
| WO2016086147A1 (en) * | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| EP3978530A1 (en) | 2015-02-26 | 2022-04-06 | F. Hoffmann-La Roche AG | Integrin beta7 antagonists and methods of treating crohn's disease |
| KR102891803B1 (ko) * | 2017-02-28 | 2025-11-28 | 모픽 테라퓨틱, 인코포레이티드 | αvβ6 인테그린 억제제 |
| US10875875B2 (en) * | 2017-04-26 | 2020-12-29 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| US10246451B2 (en) | 2017-04-26 | 2019-04-02 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| EP3773573A4 (en) | 2018-04-12 | 2022-04-06 | Morphic Therapeutic, Inc. | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4) (BETA7) |
| AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| HRP20250191T1 (hr) | 2018-10-30 | 2025-04-11 | Gilead Sciences, Inc. | Derivati 3-(kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-diona kao inhibitori alfa4beta7 integrina za liječenje upalnih bolesti |
| US11174256B2 (en) | 2018-10-30 | 2021-11-16 | Gilead Sciences, Inc. | Imidazopyridine derivatives |
| JP7189369B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４β７インテグリンの阻害のための化合物 |
| RS66976B1 (sr) * | 2019-10-16 | 2025-07-31 | Morphic Therapeutic Inc | Inhibiranje ljudskog integrina alfa4beta7 |
-
2020
- 2020-10-16 RS RS20250645A patent/RS66976B1/sr unknown
- 2020-10-16 AU AU2020366435A patent/AU2020366435A1/en active Pending
- 2020-10-16 AR ARP200102870A patent/AR120244A1/es unknown
- 2020-10-16 KR KR1020227015040A patent/KR20220102669A/ko active Pending
- 2020-10-16 TW TW109136036A patent/TWI775182B/zh active
- 2020-10-16 MA MA57399A patent/MA57399B1/fr unknown
- 2020-10-16 ES ES20875989T patent/ES3035561T3/es active Active
- 2020-10-16 TW TW113132607A patent/TWI900200B/zh active
- 2020-10-16 LT LTEPPCT/US2020/055986T patent/LT4045039T/lt unknown
- 2020-10-16 CU CU2022000027A patent/CU20220027A7/es unknown
- 2020-10-16 EP EP25157767.2A patent/EP4559525A3/en active Pending
- 2020-10-16 CN CN202411308053.XA patent/CN119192137A/zh active Pending
- 2020-10-16 EP EP20875989.4A patent/EP4045039B1/en active Active
- 2020-10-16 UA UAA202201185A patent/UA130059C2/uk unknown
- 2020-10-16 UY UY0001038926A patent/UY38926A/es unknown
- 2020-10-16 PH PH1/2022/550886A patent/PH12022550886A1/en unknown
- 2020-10-16 PL PL20875989.4T patent/PL4045039T3/pl unknown
- 2020-10-16 IL IL319053A patent/IL319053A/en unknown
- 2020-10-16 HU HUE20875989A patent/HUE071814T2/hu unknown
- 2020-10-16 BR BR112022007284A patent/BR112022007284A2/pt unknown
- 2020-10-16 JP JP2022509595A patent/JP7437490B2/ja active Active
- 2020-10-16 WO PCT/US2020/055986 patent/WO2021076890A1/en not_active Ceased
- 2020-10-16 TW TW111127993A patent/TWI802477B/zh active
- 2020-10-16 PE PE2022000633A patent/PE20221829A1/es unknown
- 2020-10-16 FI FIEP20875989.4T patent/FI4045039T3/fi active
- 2020-10-16 HR HRP20250749TT patent/HRP20250749T1/hr unknown
- 2020-10-16 CN CN202080088450.4A patent/CN115087444B/zh active Active
- 2020-10-16 US US17/769,003 patent/US20240174632A1/en active Pending
- 2020-10-16 CR CR20220205A patent/CR20220205A/es unknown
- 2020-10-16 MX MX2022004406A patent/MX2022004406A/es unknown
- 2020-10-16 JP JP2022523102A patent/JP7437495B2/ja active Active
- 2020-10-16 DK DK20875989.4T patent/DK4045039T3/da active
- 2020-10-16 WO PCT/US2020/056001 patent/WO2021076902A1/en not_active Ceased
- 2020-10-16 US US17/072,797 patent/US11104661B1/en active Active
- 2020-10-16 TW TW112116098A patent/TWI857592B/zh active
- 2020-10-16 CA CA3154269A patent/CA3154269A1/en active Pending
- 2020-10-16 SI SI202030622T patent/SI4045039T1/sl unknown
- 2020-10-16 MD MDE20220933T patent/MD4045039T2/ro unknown
- 2020-10-16 PT PT208759894T patent/PT4045039T/pt unknown
-
2021
- 2021-07-16 US US17/378,282 patent/US11370773B1/en active Active
- 2021-10-15 CN CN202180083775.8A patent/CN116783161A/zh active Pending
- 2021-10-15 TW TW110138309A patent/TWI791304B/zh active
- 2021-10-15 AU AU2021361031A patent/AU2021361031A1/en active Pending
- 2021-10-15 WO PCT/US2021/055196 patent/WO2022081983A1/en not_active Ceased
- 2021-10-15 TW TW111149835A patent/TWI840047B/zh active
- 2021-10-15 EP EP21881178.4A patent/EP4228634A4/en active Pending
- 2021-10-15 TW TW113110859A patent/TWI888065B/zh active
- 2021-10-15 JP JP2021576053A patent/JP7209116B2/ja active Active
- 2021-10-15 KR KR1020237015039A patent/KR20230088376A/ko active Pending
-
2022
- 2022-04-05 ZA ZA2022/03872A patent/ZA202203872B/en unknown
- 2022-04-13 DO DO2022000081A patent/DOP2022000081A/es unknown
- 2022-04-14 CL CL2022000959A patent/CL2022000959A1/es unknown
- 2022-04-14 IL IL292296A patent/IL292296B2/en unknown
- 2022-05-02 CO CONC2022/0005759A patent/CO2022005759A2/es unknown
- 2022-05-16 EC ECSENADI202238978A patent/ECSP22038978A/es unknown
-
2023
- 2023-01-06 JP JP2023000761A patent/JP7500785B2/ja active Active
- 2023-03-30 ZA ZA2023/03992A patent/ZA202303992B/en unknown
-
2024
- 2024-02-09 JP JP2024018866A patent/JP7702004B2/ja active Active
- 2024-02-09 JP JP2024018765A patent/JP7717202B2/ja active Active
- 2024-06-05 JP JP2024091304A patent/JP2024116230A/ja active Pending
-
2025
- 2025-02-19 DO DO2025000034A patent/DOP2025000034A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22038978A (es) | INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA | |
| CL2019003144A1 (es) | Formulaciones de anticuerpos anti-lag3 y co-formulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. | |
| CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| UY38353A (es) | Inhibición de integrina alfavbeta6 | |
| MX2022009056A (es) | Inhibidores de integrina ?v?6. | |
| MX2024008096A (es) | Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica. | |
| CL2018002814A1 (es) | Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel. | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| MX374501B (es) | Formulaciones de anticuerpos de her2 subcutáneas. | |
| SV2018005610A (es) | Derivados de oxopiridina sustituidos | |
| DOP2015000304A (es) | Inhibidores cristalinos de bromodominios | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| UY34278A (es) | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades | |
| ECSP13012648A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| DOP2013000047A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| CR20130058A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| UY33707A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| CR20130074A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| CL2015002835A1 (es) | Nuevos derivados de piridina | |
| UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
| CY1123366T1 (el) | Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου | |
| CL2019003670A1 (es) | Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta. | |
| EP3585818A4 (en) | ANTI-HLA-DQ2.5 / 8 ANTIBODIES AND ITS USE FOR THE TREATMENT OF C LIATIC DISEASE | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. |